Trial 0S-10-2

Prospective, Longitudinal, Multi-National Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma.

Type: Observational
Phase: Observational
Status: Closed to Accrual with Ongoing Follow-up
Treatments:
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Anil Tulpule, M.D.
Other Trial Staff: Christine Duran, D.M., Teh-Chun Wang, R.N.

Staff may log in to see study documents.

You may participate in this study if:

	Requirement
1	Aggressive natural killer (NK)-cell leukemia
2	Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
3	Angioimmunoblastic T-cell lymphoma
4	Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
5	PTCL, not otherwise specified
6	T/NK-cell lymphoma, nasal type
7	Enteropathy-type intestinal lymphoma
8	Hepatosplenic T-cell lymphoma
9	Subcutaneous panniculitis T-cell lymphoma
10	Transformed mycosis fungoides (at diagnosis of transformation)
11	T-cell prolymphocytic leukemia (T-PLL)
12	Cutaneous T-cell lymphoma
13	Cutaneous aggressive CD8+ T-cell lymphoma
14	Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
15	Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood)
16	Other T-Cell lymphomas not excluded

You may not participate in this study if:

1	Precursor T/NK neoplasms
2	T-cell large granular lymphocytic leukemia
3	Mycosis fungoides, other than transformed mycosis fungoides
4	Sézary syndrome
5	Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.